Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Maurizio Renna*

Department of Medical Genetics, Cambridge Institute for Medical Research, Wellcome Trust, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK

Keywords: mTOR pathway, mTOR inhibitors, resistance mechanisms, cancer therapeutics, drug design

A commentary on

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
by Rodrik-Outletzguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., et al. (2016). Nature 534, 272–276. doi: 10.1038/nature17963

The mammalian target of rapamycin (mTOR) is a highly conserved serine-threonine kinase belonging to the phosphatidylinositol kinase-related protein kinases family, which plays a central role in regulation of cellular metabolism, growth, and proliferation (Figure 1A) (Wullschleger et al., 2006; Laplante and Sabatini, 2012). The PI3K-AKT-mTOR signaling axis is also one of the most commonly activated pathways in human cancers (Vivanco and Sawyers, 2002; Zoncu et al., 2011). A growing body of evidence identifies activation of mTOR signaling as a common occurrence in human cancers (Menon and Manning, 2008). Recently, activating mutations of mTOR itself have been identified through mining of human cancer genome databases (Hardt et al., 2011). Hyper-activation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors, many of which have progressed to clinical trials (Chiang and Abraham, 2007).

Among these agents, first-generation mTOR inhibitors such as rapamycin and rapalogs, inhibit mTOR by forming a complex with the immunophilin FKBP12, which then binds directly to mammalian TOR complex 1 (mTORC1), but not to mTORC2 (Guertin and Sabatini, 2009). Despite the mechanism by which FKBP12-rapamycin inhibits mTORC1 being not completely understood, the recently published structure of the mTOR catalytic domain provided additional insight, suggesting that the drug acts by blocking substrate recruitment (Yang et al., 2013).

Limitations of rapalogs-based clinical strategies (and in particular, the strong immune-suppressive effects) have pushed toward the development of a second generation of mTOR inhibitors known as ATP-competitive mTOR kinase inhibitors (TORKIs), which target the kinase domain of mTOR and inhibit its catalytic activity. From a mechanistic point of view, the advantage of these drugs rely on the ability of inhibiting the kinase activity of both the TORC1 and TORC2 complexes, while also blocking the feedback activation of PI3K/Akt signaling (Thoreen et al., 2009). Numerous TKIs have been developed and several of them are currently being tested in clinical trials (Benjamin et al., 2011). Despite the many advantages of TORKIs, some drawbacks do exist. Although a number of cancers respond to mono-therapy treatment with rapalogs and TORKIs have been proved effective in rapamycin-insensitive cell lines, resistance remains a major concern (Feldman and Shokat, 2010). Another downside of TORKIs is their potential toxicity, which raises concerns about their long-term efficacy. Given the limitations of currently available inhibitors, new approaches toward the mTOR targeting are object of intense investigation. Combinatorial strategies may provide a way to overcome such resistance and therefore improve efficacy of mTOR targeting agents in the clinical context (Feldman and Shokat, 2010).
In a recent report, Kevan Shokat and collaborators describe the development of a third class of mTOR inhibitors that overcomes resistance to existing first- and second-generation inhibitors by exploiting the juxtaposition of two drug-binding pockets (hence, the eponymous RapaLink) (Rodrik-Outmezguine et al., 2016). By means of a resistance screen performed in MCF-7 cells they identified three somatic mutations within mTOR conferring resistance to either rapamycin (namely, A2034V and F2108L, both located in the FRB-FKBP12-rapamycin-binding domain) or to the ATP competitive inhibitor AZD8055 (located in the kinase domain, at the M2327I position) (Figures 1B, C). The clinical relevance of these mutations is supported by a case report of a patient under treatment with everolimus who acquired the identical F2108L mTOR mutation after relapse (Wagle et al., 2014). More importantly, the hyperactive M2327I mutation (as well as other mTOR kinase domain mutations) has been identified in drug-naive patients (Grabiner et al., 2014). Such mutations might therefore impact the sensitivity to ATP-competitive mTOR inhibitors of some cancerous cells, regardless of the therapeutic regimen. In contrast to the FRB-domain mutations, which exhibit a similar mechanism of resistance by disrupting the interaction of mTOR with the FKBP12-rapamycin complex and ultimately the drug binding, the M2327I mutation confers hyperactivity to the kinase by an allosteric mechanism. These observations led the authors to develop a modeling approach.

**FIGURE 1** | (A) Cells grow and proliferate when nutrients, growth factors, and the energy status trigger carbohydrate catabolism and the synthesis of essential building blocks such as proteins, nucleotides, and lipids. The mammalian target of rapamycin (mTOR) is a highly conserved serine-threonine kinase, which plays a central role in regulation of cellular metabolism, growth, and proliferation. The importance of mTOR in regulation of multiple cell functions is critical for development of cancer and its strong interaction with oncogenic pathways make this kinase an attractive target for therapeutic intervention. (B–C) Schematic representation of mTOR domains and mutations isolated in rapamycin- and AZD8055-resistant cells. By means of a resistance screen/deep sequencing combined approach, clinically relevant I-II generation drug-resistant mTOR mutations (namely: A2034V, F2108L, and M2327I) were isolated. RapaLinks represent a novel class of bivalent mTOR inhibitors capable of overcoming resistance to existing first- and second-generation inhibitors (Rodrik-Outmezguine et al., 2016).
aimed at overcoming drug-resistant mutations in either the FRB or the kinase domain. In principle, a bivalent mTOR inhibitor consisting of a rapamycin-FRB-binding element appropriately linked to a TORKi would be expected to inhibit the FRB-domain mutants because the TORKi-binding site would provide high-affinity recognition. Such an inhibitor would be similarly effective against the kinase domain mutations by virtue of an intact rapamycin-binding site, thus overcoming point mutations that diminish drug binding or that hyper-activate the kinase. In order to test such hypothesis, they generated bivalent molecules constituted by rapamycin and the highly selective TORKi MLN0128, separated by an inert chemical linker so that the resulting inhibitor could simultaneously bind to both sites. RapaLink, exerted a strong signaling and growth inhibition both in vitro and in vivo, at levels comparable to rapamycin or a combination of rapamycin with MLN0128. Strikingly, the inhibitory effect of these drugs held true in both F2108L mTOR- and M2327I mTOR-expressing cells, as well as in the respective mouse xenograft models. Additionally, cells treated with RapaLink did not develop resistance to the drug for the 9-month period of the study, as opposed to cells treated with first- or second-generation mTOR inhibitors, which evolved resistance within 3 months.

To summarize, mTOR inhibition remains an attractive therapeutic option for the treatment of cancer and has the potential to play an increasingly prominent role in future treatment strategies. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors represent a promising therapeutic option for the treatment of cancer. Indeed, encouraging data from preclinical studies resulted in the initiation of multiple clinical trials. It is conceivable to speculate that this new class of mTOR inhibitors might be beneficial in patients bearing naïve hyperactive mTOR kinase domain mutations, who originally respond to rapalogs, as well as in those that have acquired resistance to rapalogs or ATP-competitive inhibitors, or both. To evaluate its potential as a cancer therapy, clinical trials will have to be performed. In particular, it will be of critical importance to assess whether these compounds cause the insurgence of novel resistance mutations, as well as to evaluate whether a higher degree of mTOR inhibition impact on their toxicity profile. Finally, it is important to note how the design of bivalent inhibitors for therapeutic purposes has not been exploited in protein kinase inhibitor design, so far. Hence, the methodological approach employed in this study could pave the way toward the design of novel bivalent inhibitors and be applied, more generally, to other disease-relevant signaling pathways.

**AUTHOR CONTRIBUTIONS**

MR conceived the work, prepared the figure, wrote and edited the manuscript.

**ACKNOWLEDGMENTS**

The author would like to thank Prof. David C. Rubinsztein (Cambridge Institute for Medical Research, University of Cambridge) for the scientific and financial support Wellcome Trust (Grant no.: 095317/Z/11/Z).

**REFERENCES**

Benjamin, D., Colombi, M., Moroni, C., and Hall, M. N. (2011). Rapamycin passes the torch: a new generation of mTOR inhibitors. *Nature Rev. Drug Discov.* 10, 868–880. doi: 10.1038/nrd3531

Chiang, G. G., and Abraham, R. T. (2007). Targeting the mTOR signaling network in cancer. *Trends Mol. Med.* 13, 433–442. doi: 10.1016/j.molmed.2007.08.001

Feldman, M. E., and Shokat, K. M. (2010). New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). *Curr. Top. Microbiol. Immunol.* 347, 241–262. doi: 10.1007/82_2010_64

Grabber, B. C., Nardi, V., Bissoy, K., Possemato, R., Shen, K., Sinha, S., et al. (2014). A diverse array of cancer-associated mTOR mutations are hyperactivating and can predict rapamycin sensitivity. *Cancer Discov.* 4, 554–563. doi: 10.1158/2159-8290.CD-13-0929

Guertin, D. A., and Sabatini, D. M. (2009). The pharmacology of mTOR inhibition. *Sci. Signal.* 2, 2–24. doi: 10.1126/scisignal.267pe24

Hardt, M., Chantaravisoot, N., and Tamanoi, F. (2011). Activating mutations of TOR (target of rapamycin). *Genes Cells* 16, 141–151. doi: 10.1111/j.1365-2443.2010.01482.x

Laplanche, M., and Sabatini, D. M. (2012). mTOR signaling in growth control and disease. *Cell* 149, 274–293. doi: 10.1016/j.cell.2012.03.017

Menon, S., and Manning, B. D. (2008). Common corruption of the mTOR signaling network in human tumors. *Oncogene* 27 S43–S51. doi: 10.1038/onc.2009.352

Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., et al. (2016). Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. *Nature* 534, 272–276. doi: 10.1038/nature17963

Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., et al. (2009). An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. *J. Biol. Chem.* 284, 8023–8032. doi: 10.1074/jbc.m900301200

Vivanco, I., and Sawyers, C. L. (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. *Nature Rev. Cancer* 2, 489–501. doi: 10.1038/nrc839

Wagle, N., Grabber, B. C., Van Allen, E. M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., et al. (2014). Response and acquired resistance to everolimus in anaplastic thyroid cancer. *N. Engl. J. Med.* 371, 1426–1433. doi: 10.1056/nejmoa1403352

Wullschleger, S., Loewith, R., and Hall, M. N. (2006). TOR signaling in growth and metabolism. *Cell* 124, 471–484. doi: 10.1016/j.cell.2006.01.016

Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., and Pavletich, N. P. (2013). mTOR kinase structure, mechanism and regulation. *Nature* 497, 217–223. doi: 10.1038/nature12122

Zoncu, R., Efeyan, A., and Sabatini, D. M. (2011). mTOR: from the torch: a new generation of mTOR inhibitors. *Nature Rev. Drug Discov.* 10, 21–35. doi: 10.1038/nrd3535

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Renna. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.